single mode of action that the combination product can deliver with respect to its intended use. Identifying the PMOA is crucial, as it determines the appropriate regulatory pathway and involves collaboration between relevant FDA offices.

According to 21 CFR § 3.2(e), a combination product can be classified as:

• Drug and Device
• Biologic and Device
• Drug and Biologic

Understanding the product’s classification is essential for compliance with both GMP and design control requirements.

Regulatory Framework for Design Controls

Design controls are mandatory for combination products as stipulated in various regulations including 21 CFR Part 820 (Quality System Regulation) and are further enhanced through the application of design control principles outlined in device regulations. Design controls ensure that product development meets safety and efficacy standards expected by the FDA.

Each stage of the product development lifecycle—ranging from concept through design, manufacturing, and post-market activities—must incorporate design control principles. The key elements of design controls include:

• Design Input: Establishing requirements that include user needs, intended use, and regulatory requirements.
• Design Output: Ensuring that the product design meets the design input requirements.
• Design Review: Periodic evaluations to verify that the design is progressing appropriately.
• Design Verification: Confirming that the design outputs meet the design inputs.
• Design Validation: Ensuring that the finished product conforms to user needs and intended uses.
• Design History File (DHF): A compilation of records that demonstrate that the design has been developed in accordance with the requirements of the design control process.

Collectively, these elements work to mitigate risks associated with the development and manufacture of combination products and significantly improve the likelihood of compliance upon FDA review.

Good Manufacturing Practices (GMP) Expectations

Good Manufacturing Practices are regulatory requirements for systems that assure proper design, monitoring, and control throughout the manufacturing process. For combination products, compliance with GMP is critical not only for the individual components (device and drug or biologic) but for the integrated product as a whole.

The FDA’s Guidance on Combination Products specifies that the quality systems must be established and maintained as described in 21 CFR Parts 210, 211, and 820. This means that the organization must incorporate quality considerations early in the product lifecycle to ensure that both safety and efficacy are built into the product from its inception.

Key aspects of combination GMP include:

• Quality Management System (QMS): A comprehensive system that ensures consistent quality across products and processes.
• Risk Management: Proactively identifying, analyzing, and controlling risks throughout the product lifecycle.
• Documentation: Ensuring that all processes are documented adequately, including standard operating procedures (SOPs) that are maintained and routinely reviewed.
• Training: Ongoing training for employees involved in the design and manufacturing processes is critical for maintaining compliance.

The intersection of GMP and design control plays a pivotal role in ensuring that combination products not only comply with regulatory standards but also meet consumer safety and quality expectations effectively.

OPQ and CDRH Coordination

In the context of combination products, effective coordination between the Office of Pharmaceutical Quality (OPQ) and the Center for Devices and Radiological Health (CDRH) is essential. This integrated approach enables seamless oversight of products that integrate pharmaceutical and device components, thereby providing comprehensive regulation that addresses the unique challenges posed by combination products.

Developing a well-defined communication plan that outlines the roles and responsibilities of both the OPQ and CDRH team members can mitigate potential bottlenecks experienced during the regulatory review process. As combination products navigate dual pathways, the following strategies are vital:

• Joint Review Processes: Establishing concurrent review frameworks where both OPQ and CDRH evaluators participate in product evaluations.
• Cross-Training: Facilitating opportunities for cross-training among FDA personnel to promote a greater understanding of the complexities associated with combination products.
• Integrated Submission Dockets: Utilizing methods that facilitate combined submissions to minimize redundant requests and streamline the review timeline.

Establishing and maintaining an effective mechanism for OPQ and CDRH coordination is necessary for the success of combination product development and commercialization.

Developing Platform Devices

Platform devices represent a specific category of combination products that utilize a core technological foundation from which various product variations are developed and manufactured. These products can address a range of indications through modular design. Given their unique characteristics, platform devices require tailored strategies for both regulatory compliance and market entry.

The development of platform devices necessitates a thorough understanding of both the initial product’s PMOA and any variations that may arise in subsequent iterations or combinations. Regulatory implications may shift based on how these devices are categorized and positioned within the market. Thus, organizations should consider the following:

• Design Flexibility: Ensuring that platform products maintain design efficiency while accommodating customization for specific applications.
• Post-Market Surveillance: Establishing robust systems to monitor safety and effectiveness once the platform products are on the market.
• Regulatory Strategies: Engaging with the FDA early in the developmental phase to discuss intended uses and clarify the regulatory pathway for novel variations of platform devices.

The use of platform devices can significantly increase the marketability and scalability of combination products, provided that regulatory considerations are diligently factored into both design and development phases.

Post-Market Safety and Compliance

The post-market phase of combination products involves continuous monitoring to ensure safety and efficacy, as well as adherence to all regulatory requirements. The FDA mandates that manufacturers demonstrate compliance through a combination of adverse event reporting, follow-up studies, and risk management assessments.

To maintain compliance throughout the post-market lifecycle, combination product manufacturers should implement the following practices:

• Adverse Event Reporting: Establish streamlined processes for healthcare providers and consumers to report any adverse events. This includes fulfilling reporting mandates as delineated in regulatory guidance.
• Risk Management Activities: Continuously assess and mitigate risks through systematic post-market surveillance and analysis of real-world data. Effective risk management throughout the lifecycle is key to sustaining compliance.
• Periodic Safety Update Reports (PSUR): Regularly updating stakeholders on the safety and efficacy of combination products through well-structured PSURs.

Maintaining a proactive post-market surveillance strategy helps in identifying issues early, allowing for timely interventions that reassure regulators and consumers about product safety.

Conclusion

As the development and regulation of combination products become more intricate, the necessity for comprehensive understanding of design controls and GMP expectations is paramount for success in the market. Regulatory, quality, clinical, and RA/QA professionals must work collaboratively across disciplines to ensure compliance with the evolving FDA landscape, addressing the needs intrinsic to both drug and device components. By fostering an understanding of the principles discussed in this guide, teams can enhance their approach to regulatory compliance and improve outcomes for combination products.